Aescuvest
Aescuvest is a leading, healthcare dedicated FinTech company, with a special focus on financing digital healthcare solutions. Aescuvest’s mission is to facilitate and enable impactful investments into medical breakthrough innovation to disrupt and improve healthcare delivery models, products, and services. Aescuvest enables its investors to build their very individual portfolio of healthcare start-ups - according to their personal investment focus.
A cooperation with EIT Health, and a growing network of partnerships across Europe, allow Aescuvest to source and evaluate the most promising healthcare investment opportunities, structure their financing rounds, and enable healthcare technology-driven investors, such as Business Angels, HNWIs, Family Offices, and Corporate Investors, to participate in healthcare investment opportunities by direct investments via SPV structures.
The Investment Committee, composed of Aescuvest’s very own investment team and members of the Advisory Board of Aescuvest, both deeply rooted in the healthcare industry and with proven track records, have developed a strong and over the last years well tested, pre-screening and due diligence process, to identify and select healthcare start-ups. Aescuvest’s Management is committing own capital to each company prior introduction to the wider Aescuvest investor base.
The combination of innovative ways for equity capital provision, with healthcare industry and investment expertise, provides the Aescuvest portfolio companies a unique platform to develop their business solution, accelerate their path towards commercialization, and lower market access barriers.
Since inception, Aescuvest has successfully raised 30,5 million Euro for its companies and shows roughly 11 million Euro raised capital in 2021 alone.
0
0
0
Key Info
- 2014 Founded
- Frankfurt, Germany
- 1 Investment
- •••••••••
News
There are no recent news for this organization.
Activity Timeline
Apr 25, 2023
Team
Investments
Date | Company | Round | Amount | Investors |
---|---|---|---|---|
Apr 25, 2023 | Series B | $13,000,000 |